COMMUNIQUÉS West-GlobeNewswire

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
16/04/2025
Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced [...]
Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
16/04/2025
MONTREAL, April 16, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara Biotech Inc. annoncera ses résultats financiers pour le deuxième trimestre de l'exercice 2025 le 28 avril 2025
16/04/2025
MONTRÉAL, 16 avr. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara » , « la Société » , « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis [...]
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
16/04/2025
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of [...]
Spectral Medical Completes Tigris Trial Enrollment
16/04/2025
157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “ [...]
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
16/04/2025
LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced [...]
Sustanon 250: Sustanon Testosterone Cycle Results, Buy Top Sustanon 250 Injection Alternative For Bodybuilding By CrazyBulk
16/04/2025
Sustanon 250 Injections and Sustanon Testosterone are testosterone boosters. According to the maker, they are safe to use and employ natural ingredients to boost overall health and wellness. Albany, New York, April 16, [...]
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
16/04/2025
RECORDATI: FDA GRANTS ISTURISA ® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA ® is a cortisol synthesis inhibitor that blocks the [...]
Glutathione Tablets: RediClinic Offers 20% Off on Pure Japanese Glutathione Tablets for Skin Whitening
16/04/2025
New York, April 15, 2025 (GLOBE NEWSWIRE) -- Glutathione Tablets: RediClinic Offers 20% Off on Pure Japanese Glutathione Tablets for Skin Whitening Rediclinic glutathione tablets Content promoted by Branding Ex solution [...]
Prime Biome (Updated 2025): A Comprehensive Review of the Groundbreaking Skin-Gut Axis Supplement
16/04/2025
Clinically Inspired Gut-Skin Axis Supplement Prime Biome Faces Real Consumer Feedback and Scientific Scrutiny—Here’s What the Data and Verified Users Reveal in 2025 ST. PETERSBURG, Fla., April 16, 2025 (GLOBE NEWSWIRE [...]
Conditional Issuance of Shares
16/04/2025
INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), [...]
Émission Conditionnelle d’Actions
16/04/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Émission Conditionnelle d’Actions Mont-Saint-Guibert, Belgique – le 16 avril 2025, 8:00h CET / 2:00h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” ou la “ [...]
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
16/04/2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Santhera shares updates on commercial rollout of AGAMREE®
16/04/2025
Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from [...]
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
16/04/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority ( obere kantonale Nachlassbehörde [...]
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
16/04/2025
Total sales growth of 11.6% at CER 1 , or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib regulatory submission to EMA 2 for [...]
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l’exercice 2025
16/04/2025
Croissance des ventes de 11,6% à taux de change constant 1 , ou 11,7% en données publiées, tirée par toutes les aires thérapeutiques, incluant une contribution croissante d'Iqirvo et de Bylvay. Soumission réglementaire [...]
Automated Health Systems Expands Access to Public Healthcare Nationwide with Smarter Solutions
16/04/2025
Dr. Moses Haregewoyn leads Automated Health Systems, which uses technology and structured management to expand access to public healthcare for individuals, providers, and agencies. The company has grown steadily by [...]
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
16/04/2025
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are [...]

Pages